[Polypharmacy-guideline issued by the Department of Internal Medicine (DIM) at t...

연구 요약

[Polypharmacy-guideline issued by the Department of Internal Medicine (DIM) at the University Hospital Zurich (USZ)].

Praxis 학술지에 발표된 이 연구는 Neuner-Jehle S, Rosemann A, Senn O 외 연구팀이 수행하였습니다.

이 연구는 '[Polypharmacy-guideline issued by the Department of Internal Medicine (DIM) at the University Hospital Zurich (USZ)].'에 대한 과학적 분석을 제공합니다.

핵심 내용

The proportion of elderly people with several diseases (multimorbidity), who need four or more drugs daily (polypharmacy), is stea-dily increasing. Evidence on the efficacy and safety of drugs in this patient population is limited, as they are often underrepresented or exclu-ded from clinical trials. Most guidelines focus on single diseases and only occasionally address the challenges of pharmacotherapy for older, multimorbid patients taking multiple drugs. A regular and structured evaluation of the medication is therefore essential. The decision-making process for further therapy should consider not only existing diagnoses, but also the individual situation and life goals of the patients. Reducing or discontinuing of drugs (deprescribing) may be appropriate in individual cases; however, undertreatment must be avoided.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41784519)